StockNews.AI

Illumina Announces Preliminary Unaudited Financial Results for Fourth Quarter and Fiscal Year 2025

StockNews.AI • 1 minute

SOMAILMN
High Materiality8/10

Information

SAN DIEGO, Jan. 13, 2026 /PRNewswire/ -- Illumina, Inc. (Nasdaq: ILMN) ("Illumina" or the "company")...

Original source

AI Summary

Illumina reports Q4 2025 revenue of $1.155 billion, up 5% from Q4 2024. Full fiscal year 2025 revenue is flat at $4.34 billion compared to 2024. Non-GAAP EPS for Q4 2025 projected between $1.27 and $1.30. SomaLogic acquisition poses risks impacting future growth and market position. Financials subject to adjustments pending completion of annual audits.

Sentiment Rationale

The revenue growth demonstrates resilience in a challenging market, indicating potential for investor confidence. Historical data shows similar financial recoveries boosting stock prices.

Trading Thesis

Earnings reports influence immediate investor sentiment; sustained growth could drive longer-term effects. Previous quarterly reports had similar impacts on stock performance shortly after announcements.

Market-Moving

  • Illumina reports Q4 2025 revenue of $1.155 billion, up 5% from Q4 2024.
  • Full fiscal year 2025 revenue is flat at $4.34 billion compared to 2024.
  • Non-GAAP EPS for Q4 2025 projected between $1.27 and $1.30.

Key Facts

  • Illumina reports Q4 2025 revenue of $1.155 billion, up 5% from Q4 2024.
  • Full fiscal year 2025 revenue is flat at $4.34 billion compared to 2024.
  • Non-GAAP EPS for Q4 2025 projected between $1.27 and $1.30.
  • SomaLogic acquisition poses risks impacting future growth and market position.
  • Financials subject to adjustments pending completion of annual audits.

Companies Mentioned

  • SOMA (SOMA)
  • ILMN (ILMN)

Earnings

Positive preliminary results indicate operational performance, likely inducing short-term stock price fluctuations.

Illumina Releases Preliminary Financial Results for Q4 and Fiscal Year 2025

Company Symbol: ILMN

Overview of Preliminary Results

Illumina, Inc. (NASDAQ: ILMN) has announced its preliminary unaudited financial results for the fourth quarter and fiscal year 2025. The announcement comes ahead of its scheduled presentation at the 44th Annual J.P. Morgan Healthcare Conference, set for January 13, 2026, at 7:30 a.m. Pacific Time (10:30 a.m. Eastern Time). Investors can view the webcast on Illumina's investor relations website at investor.illumina.com.

Financial Highlights for Q4 2025

  • Revenue: Approximately $1.155 billion, representing a 5% increase from Q4 2024 (or 4% increase on a constant currency basis).
  • Ex-China revenue: Approximately $1.100 billion, up 7% from Q4 2024 (and unchanged on a constant currency basis).
  • GAAP diluted EPS: Expected between $2.14 to $2.17.
  • Non-GAAP diluted EPS: Expected between $1.27 to $1.30.

Fiscal Year 2025 Financial Overview

  • Revenue: Approximately $4.34 billion, flat compared to 2024 (also flat on a constant currency basis).
  • Ex-China revenue: Approximately $4.10 billion, up 2% from 2024 (and unchanged on a constant currency basis).
  • GAAP diluted EPS: Expected between $5.42 to $5.45.
  • Non-GAAP diluted EPS: Expected between $4.76 to $4.79.

Future Reporting Dates

Illumina plans to provide full detailed results for the fourth quarter and fiscal year 2025 on February 5, 2026, following the close of market. The preliminary results presented here may be subject to adjustments following the completion of accounting and annual audit procedures.

Understanding Non-GAAP Financial Measures

The company also highlights its use of non-GAAP financial measures, which include metrics such as diluted earnings per share, net income, operating expenses, and free cash flow. These non-GAAP measures exclude certain costs, enabling investors to better assess the company’s operating performance. The board of directors utilizes these measures to evaluate management performance and set compensation.

Investors are encouraged to review both GAAP and non-GAAP financial results to gain a comprehensive understanding of the company's performance. Reconciliations between these financial presentations are available in the accompanying tables of the release.

Forward-Looking Statements and Market Considerations

This release contains forward-looking statements regarding Illumina's performance and initiatives that are subject to risks and uncertainties. Factors that may influence results include:

  • Changes in market demand, particularly in the proteomics sector.
  • The timing and mix of customer orders.
  • The progress of ongoing regulatory approvals, including the anticipated acquisition of SomaLogic, Inc.
  • External economic conditions, including potential tariffs and trade policies.

Illumina emphasizes the unpredictability of these factors and their potential impact on future results. Investors should stay informed by reviewing the company's filings with the Securities and Exchange Commission, including Forms 10-K and 10-Q.

Related News